Business Context and Reporting Period
Company: MediciNova, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 10, 2010
Event: Entry into a Material Definitive Agreement (Loan and Security Agreement) with Oxford Finance Corporation.
Key Financial Metrics and Transaction Details
- Loan Amount: $15.0 million.
- Interest Rate: 12.87% per annum.
- Use of Proceeds: Working capital and continued clinical development of MN-221.
- Security: First priority security interest in substantially all assets (excluding intellectual property); guaranteed by subsidiary Avigen, Inc.
- Upfront Costs: $150,000 facility fee paid; $450,000 deferred interest payment due June 30, 2011.
- Equity Component: Issuance of a warrant to purchase 198,020 shares (approx. 1.2% fully diluted) at an exercise price of $6.06 per share.
- Repayment Terms: Interest-only payments monthly through February 1, 2011; principal and interest in 30 equal monthly installments from March 1, 2011, to maturity on August 1, 2013.
Material Changes and Covenants
The filing discloses a significant increase in debt obligations and the creation of a direct financial obligation. The agreement includes strict affirmative and restrictive covenants, most notably a milestone requirement by March 31, 2011. MediciNova must achieve one of the following:
- Enter into a collaboration or partnership generating at least $15.0 million in upfront cash proceeds or securities conversion proceeds.
- Receive positive Phase IIB data on MN-221, or obtain FDA approval to proceed to Phase III following a positive end-of-phase II meeting.
Failure to meet these covenants or other defaults (including payment defaults or material adverse changes) will trigger a 5 percentage point increase in the interest rate and immediate acceleration of all outstanding obligations.
Guidance, Risks, and Unusual Items
- Prepayment Penalties: 3% if prepaid before May 10, 2011; 2% between May 11, 2011, and May 10, 2012; 1% thereafter.
- Restrictions: Limitations on additional indebtedness, liens, mergers, asset dispositions, and distributions.
- Risk of Default: The high interest rate and strict milestone covenants pose a liquidity risk if clinical development or partnership negotiations do not proceed as planned.
Investor Verification Checklist
- Verify the current status of MN-221 clinical trials and the likelihood of meeting the March 31, 2011 milestone.
- Confirm the company's cash runway relative to the interest-only payment schedule and the deferred interest obligation.
- Review the impact of the warrant issuance on potential future dilution.
- Assess the company's ability to secure the required $15.0 million in partnership proceeds if clinical data is not positive by the deadline.